Trial Profile
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant-mesothelioma; Peritoneal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 26 Apr 2023 Planned primary completion date changed from 20 Mar 2023 to 20 Mar 2024.
- 18 Apr 2022 Planned End Date changed from 20 Mar 2023 to 20 Mar 2024.
- 18 Apr 2022 Planned primary completion date changed from 20 Mar 2022 to 20 Mar 2023.